GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » Cash Ratio

CohBar (CohBar) Cash Ratio : 4.10 (As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is CohBar Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. CohBar's Cash Ratio for the quarter that ended in Jun. 2023 was 4.10.

CohBar has a Cash Ratio of 4.10. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for CohBar's Cash Ratio or its related term are showing as below:

CWBR' s Cash Ratio Range Over the Past 10 Years
Min: 1.01   Med: 11.29   Max: 33.59
Current: 4.1

During the past 10 years, CohBar's highest Cash Ratio was 33.59. The lowest was 1.01. And the median was 11.29.

CWBR's Cash Ratio is ranked better than
58.15% of 1491 companies
in the Biotechnology industry
Industry Median: 2.98 vs CWBR: 4.10

CohBar Cash Ratio Historical Data

The historical data trend for CohBar's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar Cash Ratio Chart

CohBar Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.26 6.16 6.84 15.54 15.22

CohBar Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.01 33.59 15.22 15.66 4.10

Competitive Comparison of CohBar's Cash Ratio

For the Biotechnology subindustry, CohBar's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CohBar's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CohBar's Cash Ratio distribution charts can be found below:

* The bar in red indicates where CohBar's Cash Ratio falls into.



CohBar Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

CohBar's Cash Ratio for the fiscal year that ended in Dec. 2022 is calculated as:

Cash Ratio (A: Dec. 2022 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=15.737/1.034
=15.22

CohBar's Cash Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash Ratio (Q: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=12.311/3.002
=4.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CohBar  (OTCPK:CWBR) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


CohBar Cash Ratio Related Terms

Thank you for viewing the detailed overview of CohBar's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


CohBar (CohBar) Business Description

Traded in Other Exchanges
N/A
Address
1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025
CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.
Executives
Stephanie Tozzo director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret director, officer: Chief Executive Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno officer: CFO, Treasurer and Secretary 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle officer: Chief Executive Officer C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern director, officer: Chief Executive Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025